← Back to Search
Selective Intracellular Delivery Of Proteasome Inhibitors Through PH-sensitive Polymeric Micelles Directed To Efficient Antitumor Therapy.
S. Quader, H. Cabral, Y. Mochida, T. Ishii, X. Liu, K. Toh, H. Kinoh, Y. Miura, N. Nishiyama, Kazunori Kataoka
Published 2014 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
The ubiquitin-proteasome system is central in the regulation of cellular proteins controlling cell cycle progression and apoptosis, drawing much interest for developing effective targeted cancer therapies. Herein, we developed a novel pH-responsive polymeric-micelle-based carrier system to effectively deliver the proteasome inhibitor MG132 into cancer cells. MG132 is covalently bound to the block copolymer composed of polyethylene glycol (PEG) and polyaspartate through an acid-labile hydrazone bond. This bond is stable at physiological condition, but hydrolytically degradable in acidic compartments in the cell, such as late-endosomes and lysosomes, and thus, it was used for controlled release of MG132 after EPR-mediated preferential accumulation of the micelles into the tumor. MG132-loaded micelles have monodispersed size distribution with an average diameter of 45nm, and critical micelle concentration is well below 10(-7)M. In vitro studies against several cancer cell lines confirmed that MG132-loaded micelles retained the cytotoxic effect, and this activity was indeed due to the inhibition of proteasome by released MG132 from the micelles. Real-time in vitro confocal-microscopy experiments clearly indicated that MG132-conjugated micelles disintegrated only inside the target cells. By intravital confocal micro-videography, we also confirmed the prolonged circulation of MG132 loaded micelles in the bloodstream, which lead to tumor specific accumulation of micelles, as confirmed by in vivo imaging 24h after injection. These micelles showed significantly lower in vivo toxicity than free MG132, while achieving remarkable antitumor effect against a subcutaneous HeLa-luc tumor model. Our findings create a paradigm for future development of polymeric-micelle-based carrier system for other peptide aldehyde type proteasome inhibitors to make them effective cohort of the existing cancer therapeutic regiments.
This paper references
Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting
M. Murakami (2011)
Proteasome inhibition: A novel mechanism to combat asthma.
P. Elliott (1999)
Proteasome inhibitors: Dozens of molecules and still counting.
Geoffroy de Bettignies (2010)
Fluorescent membrane probes incorporating dipyrrometheneboron difluoride fluorophores.
I. Johnson (1991)
Proteasome inhibitors: an expanding army attacking a unique target.
A. Kisselev (2012)
Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
S. Goktas (2010)
Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels.
A. Mikhail (2009)
Proteasome inhibitors can alter the signaling pathways and attenuate the P‐glycoprotein‐mediated multidrug resistance
T. Fujita (2005)
pH-Responsive copolymer assemblies for controlled release of doxorubicin.
E. Gillies (2005)
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp
Y. Zhang (2008)
The ubiquitin‐proteasome pathway and proteasome inhibitors
J. Myung (2001)
Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change.
Y. Bae (2003)
Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery.
A. Lavasanifar (2002)
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
M. Bentires-Alj (2003)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
Determination of the Critical Micelle Concentration of Block Copolymer Micelles by Static Light Scattering
K. Khougaz (1994)
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Y. Ogiso (2000)
Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers.
Younsoo Bae (2009)
Nanocarriers as an emerging platform for cancer therapy.
D. Peer (2007)
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
R. Plummer (2011)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
K. Neubert (2008)
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.
T. Zollner (2002)
Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132.
A. Ahmed (2010)
The proteasome: a suitable antineoplastic target
Julian T. Adams (2004)
Block copolymer micelles as vehicles for drug delivery
Kataoka Kazunori (1993)
Subcellular localization of proteasomes and their regulatory complexes in mammalian cells.
P. Brooks (2000)
Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.
R. Duncan (2012)
MG132, a proteasome inhibitor, induces apoptosis in tumor cells
Na Guo (2013)
NC‐6300, an epirubicin‐incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin
Amane Takahashi (2013)
Proteasome inhibitors as therapeutic agents: current and future strategies.
J. Delcros (2003)
c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer.
J. Jung (2012)
Anthracyclines, proteasome activity and multi-drug-resistance
Mirela R Fekete (2005)
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
S. Nawrocki (2004)
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Y. Matsumura (2009)
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
S. D. Catz (2001)
Selective Inhibitors of the Proteasome-dependent and Vacuolar Pathways of Protein Degradation in Saccharomyces cerevisiae *
D. H. Lee (1996)
A transgenic mouse model of the ubiquitin/proteasome system
K. Lindsten (2003)
Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy.
Y. Bae (2005)
Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation.
Shencun Fang (2012)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.
H. Cabral (2011)
Development of proteasome inhibitors as research tools and cancer drugs
A. Goldberg (2012)
Preparation of micelle-forming polymer-drug conjugates.
M. Yokoyama (1992)
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis
N. Schmidt (2010)
Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system
A. Ludwig (2009)
Proteasome inhibition for antibody-mediated rejection
J. Everly (2009)
Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery.
Y. Bae (2005)
Bortezomib for the Treatment of Mantle Cell Lymphoma
R. Kane (2007)
Proteasome inhibition: a new anti-inflammatory strategy
P. Elliott (2003)
Nanocarriers’ entry into the cell: relevance to drug delivery
H. Hillaireau (2009)
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
K. Rock (1994)
This paper is referenced by
Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
P. Mi (2020)
Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery
R. Mo (2016)
Proteasome Inhibitor-Loaded Micelles Enhance Antitumor Activity Through Macrophage Reprogramming by NF-κB Inhibition.
Hailiang Wu (2017)
cRGD peptide‐installed epirubicin‐loaded polymeric micelles for effective targeted therapy against brain tumors
S. Quader (2017)
RGD(Arg-Gly-Asp) internalized docetaxel-loaded pH sensitive liposomes: Preparation, characterization and antitumor efficacy in vivo and in vitro.
Tiantian Zuo (2016)
Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine
Amber Gonda (2019)
Linear polyethyleneimine-doxorubicin conjugate for pH-responsive synchronous delivery of drug and microRNA-34a
Hyosook Jung (2015)
Biodegradable and Biocompatible Polymers‐Based Drug Delivery Systems for Cancer Therapy
Ibrahim M. El-Sherbiny (2015)
Structural modifications in polymeric micelles to impart multifunctionality for improved drug delivery.
Anupama Mittal (2016)
Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy
R. Cheng (2015)
Survey of supercritical fluid techniques for producing drug delivery systems for a potential use in cancer therapy
A. Tabernero (2016)
Hydrazone linkages in pH responsive drug delivery systems
Sandeep J. Sonawane (2017)
Self-assembly of pH-sensitive fluorinated peptide dendron functionalized dextran nanoparticles for on-demand intracellular drug delivery
Shengnan Ma (2015)
Co-delivery of drugs and plasmid DNA for cancer therapy.
Pei Yun Teo (2016)
Nanomaterial-Enabled Cancer Therapy.
S. Quader (2017)
pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents.
Mahdi Karimi (2016)
Controlled Fab installation onto polymeric micelle nanoparticles for tuned bioactivity
Shaoyi Chen (2017)
Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors
Hongsai Chen (2018)
Block copolymer prodrugs: Synthesis, self-assembly, and applications for cancer therapy.
Debabrata Dutta (2019)
Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors.
S. S. Kesharwani (2019)
Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG132
Y. Matsumoto (2016)
Highly stable RGD/disulfide bridge-bearing star-shaped biodegradable nanocarriers for enhancing drug-loading efficiency, rapid cellular uptake, and on-demand cargo release
Jianqin Yan (2018)
Reduction-sensitive micelles with sheddable PEG shells self-assembled from a Y-shaped amphiphilic polymer for intracellular doxorubicine release.
C. Cui (2015)
Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery
Y. Fang (2017)
A novel pH-sensitive carrier for the delivery of antitumor drugs: histidine-modified auricularia auricular polysaccharide nano-micelles
Yingying Wang (2017)
High-Resolution Plasma Membrane-Selective Imaging by Second Harmonic Generation
Takaha Mizuguchi (2018)
Cytotoxicity Enhancement of Paclitaxel by Loading on Stearate-g-dextran Micelles on Breast Cancer Cell Line MCF-7
F. Ghaffari (2018)
pH-Responsive Polypeptide-Based Smart Nano-Carriers for Theranostic Applications
Rimesh Augustine (2019)
Synthetic polypeptides: from polymer design to supramolecular assembly and biomedical application.
Z. Song (2017)
Synthesis and evaluation of cholesterol-grafted PEGylated peptides with pH-triggered property as novel drug carriers for cancer chemotherapy.
C. Zhang (2016)
Glucose-Responsive Microspheres as a Smart Drug Delivery System for Controlled Release of Insulin
Jiaojiao Yu (2019)
MPEG-DSPE polymeric micelle for translymphatic chemotherapy of lymph node metastasis.
X. Li (2015)See more